RT Book, Section
A1 Hajjar, Katherine A.
A1 Ruan, Jia
A2 Kaushansky, Kenneth
A2 Prchal, Josef T.
A2 Burns, Linda J.
A2 Lichtman, Marshall A.
A2 Levi, Marcel
A2 Linch, David C.
SR Print(0)
ID 1180470960
T1 Fibrinolysis and Thrombolysis
T2 Williams Hematology, 10e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260464122
LK hemonc.mhmedical.com/content.aspx?aid=1180470960
RD 2024/04/20
AB SUMMARYImproved  understanding  of  the  molecular  mechanisms  of  fibrinolysis  has  led  to  major  advances  in  fibrinolytic  and  antifibrinolytic  therapy.  Characterization  of  the  genes  for  all  the  major  fibrinolytic  proteins  revealed  the  structure  of  the  relevant  serine  proteases,  their  inhibitors,  and  their  receptors.  The  development  of  genetically  engineered  animals  deficient  in  one  or  more  fibrinolytic  protein(s)  revealed  both  expected  and  unexpected  functions,  including  those  relating  to  tissue  remodeling,  inflammation,  and  vascular  integrity.  In  addition,  we  now  have  a  catalog  of  acquired  and  inherited  disorders  reflective  of  either  fibrinolytic  deficiency  with  thrombosis  or  fibrinolytic  excess  with  hemorrhage.  These  advances  have  led  to  development  of  more  effective  and  safer  protocols  for  both  profibrinolytic  and  antifibrinolytic  therapy  in  a  variety  of  circumstances.